Universal nirsevimab slashes RSV infant hospitalizations, study suggests
Giving the long-acting monoclonal antibody nirsevimab to most infants sharply decreased hospitalizations and clinic visits linked to respiratory syncytial virus ...
Giving the long-acting monoclonal antibody nirsevimab to most infants sharply decreased hospitalizations and clinic visits linked to respiratory syncytial virus ...
Respiratory virus activity across the United States has climbed to high levels, driven by increases in influenza and respiratory syncytial ...
In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also reduce these ...
COVID-19 rates in the United States and Europe remain low, but influenza and respiratory syncytial virus (RSV) activity is ramping ...
Credit: CC0 Public Domain A wave of the highly contagious respiratory syncytial virus is beginning to wash over the United ...
The team found that XBB.1.5-adapted COVID-19 mRNA vaccines had a pooled vaccine effectiveness (VE) against hospitalization of 46% to 50% ...
Transmission electron micrograph of RSV. Credit: CDC/ Dr. Erskine Palmer / Public Domain A new Cochrane review demonstrates that vaccines ...
Pediatric hospitals across the United States saw a surge in respiratory syncytial virus (RSV) in the summer of 2021 and ...
A Merck drug developed to prevent disease from respiratory syncytial virus (RSV) in infants has won FDA approval, introducing competition ...
A study of the single-dose respiratory syncytial virus (RSV) vaccine in older adults shows that vaccine efficacy waned across three ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.